49 results
8-K
EX-99.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
penalties;
Tenet may be subject to litigation or product liability claims; and
Tenet’s reputation may suffer.
Any of these events could prevent Tenet … rights, Tenet could face more litigation with respect to the validity and/or scope of patents relating to its competitors’ products. The availability
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
” means any civil, criminal, judicial, administrative or arbitral actions, suits, hearings, litigation, proceedings (public or private), claims … , custody or control of any Person other than Seller.
Section 5.6. Litigation. There is no Proceeding pending or threatened in writing, against Seller
8-K
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995
8-K
EX-99.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
or successful challenge of our patent rights, we could face more litigation with respect to the validity and/or scope of patents relating to our competitors … of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation
8-K
yng27q
26 Jun 24
Submission of Matters to a Vote of Security Holders
4:23pm
DEFA14A
xz06 ikn3jn6vf8q
14 Jun 24
Additional proxy soliciting materials
5:02pm
DEFA14A
x0lo3a8z7 mfnflsf
12 Jun 24
Additional proxy soliciting materials
4:42pm
8-K
7liohd3s
12 Jun 24
Departure of Directors or Certain Officers
4:41pm
DEFM14A
yaffb0gv8sr81
4 Jun 24
Proxy related to merger
8:00am
PREM14A
5h1t23r
17 May 24
Preliminary proxy related to merger
4:36pm
DEFA14A
b14kqwkho
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-10.5
1glrl13cwzsp82 lxw1
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-2.1
ebahn
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
xayltnveqcat7rtj vh
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.2
ikl1d6kw9qh k1imp6
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.1
paxo7rs gojrubjj
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am